Skip to main content

Phase 3 Start

JAZZ: Phase3_Start: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy

September 18, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
September 18, 2026
Company
Jazz Pharmaceuticals plc (JAZZ)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy

JAZZ overview →

Other upcoming events for JAZZ

Phase 1 StartPhase1_Start: A Phase 1, Randomized, Double-Blind, Sponsor-Unblinded, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants
Phase 3 StartPhase3_Start: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Cannabidiol Oral Solution (CBD-OS, JZP926-OS) in Participants Aged 1 Year and Older With Developmental and Epileptic Encephalopathy (DEE)
Phase 2 StartPhase2_Start: A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab
Phase 2 StartPhase2_Start: A Pilot Study, Open-Label Study of ONC201 for Refractory Meningioma
Phase 2 StartPhase2_Start: A Phase IIb Study of the Safety and Efficacy of Nabiximols in Subjects With Spasticity Due to Neuromyelitis Optica Spectrum Disorders: A Double-blind, Randomized, Placebo-Controlled, Crossover Study